Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.nature.com › articles › s41573/022/00579-0Targeting HER2-positive breast cancer: advances and future...

   www.nature.com › articles › s41573/022/00579-0

   7 Νοε 2022 · Currently, survival rates exceed 90% in HER2 + early breast cancer (EBC) treated with chemotherapy and dual antibody therapy 5.

2. www.nejm.org › doi › fullOverall Survival with Ribociclib plus Letrozole in Advanced...

   www.nejm.org › doi › full

   9 Μαρ 2022 · First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast...

3. www.nature.com › articles › s41571/023/00849-9Management of patients with advanced-stage HER2-positive breast...

   www.nature.com › articles › s41571/023/00849-9

   8 Ιαν 2024 · Several trials have investigated different and novel HER2-targeted agents in cohorts of patients with previously treated metastatic HER2 + breast cancer. Among these new therapies, TKIs...

4. www.astrazeneca.com › media-centre › press-releasesEnhertu demonstrated a median progression-free survival ... -...

   www.astrazeneca.com › media-centre › press-releases

   • Αποθηκευμένο αντίγραφο

   2 Ιουν 2024 · With a median progression-free survival of more than a year, the results from DESTINY-Breast06 show that Enhertu could become a new standard of care for patients with HER2-low- and HER2-ultralow-expressing tumours following endocrine therapy in the metastatic setting.”

5. www.cancertherapyadvisor.com › indepth › asco-2024-metastatic-breast-cancerASCO 2024: Improving Outcomes in Metastatic Breast Cancer

   www.cancertherapyadvisor.com › indepth › asco-2024-metastatic-breast-cancer

   • Αποθηκευμένο αντίγραφο

   18 Ιουν 2024 · Updated results from the phase 3 INAVO120 trial showed that adding inavolisib to palbociclib and fulvestrant can improve outcomes in patients with PIK3CA -mutated, HR-positive, HER2-negative...

6. www.thelancet.com › journals › lanepeReal-world time trends in overall survival, treatments and...

   www.thelancet.com › journals › lanepe

   11 Οκτ 2022 · The treatment landscape of HR+/HER2− advanced breast cancer is changing. New available therapies include amongst others mTOR inhibitors and CDK4/6 inhibitors. Phase 3 clinical trials on CDK4/6 inhibitors have all proved progression-free survival benefit.

7. ascopubs.org › doi › 10Current and Future Management of HER2-Positive Metastatic Breast...

   ascopubs.org › doi › 10

   2 Ιουν 2021 · Krop IE, Kim SB, Martin AG, et al: Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial.